Pharsight

Verquvo patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8420656 MERCK SHARP DOHME Substituted 5-fluoro-1H-pyrazolopyridines and their use
May, 2031

(6 years from now)

US10736896 MERCK SHARP DOHME Substituted 5-fluoro-1H-pyrazolopyridines and their use
May, 2031

(6 years from now)

US9604948 MERCK SHARP DOHME Process for preparing substituted 5-fluoro-1H-pyrazolopyridines
Nov, 2032

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8921377 MERCK SHARP DOHME Substituted 5-fluoro-1H-pyrazolopyridines and their use
May, 2031

(6 years from now)

US9993476 MERCK SHARP DOHME Substituted 5-flouro-1H-pyrazolopyridines and their use
May, 2031

(6 years from now)

US11439642 MERCK SHARP DOHME Substituted 5-fluoro-1H-pyrazolopyridines and their use
May, 2031

(6 years from now)

Verquvo is owned by Merck Sharp Dohme.

Verquvo contains Vericiguat.

Verquvo has a total of 6 drug patents out of which 0 drug patents have expired.

Verquvo was authorised for market use on 19 January, 2021.

Verquvo is available in tablet;oral dosage forms.

Verquvo can be used as reducing the risk of cardiovascular death and heart failure (hf) hospitalization following a hospitalization for hf or need for outpatient iv diuretics, in adults with symptomatic chronic hf and ejection fraction less than 45%.

Drug patent challenges can be filed against Verquvo from 19 January, 2025.

The generics of Verquvo are possible to be released after 26 November, 2032.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 19, 2026

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using VERICIGUAT ingredient

NCE-1 date: 19 January, 2025

Market Authorisation Date: 19 January, 2021

Treatment: Reducing the risk of cardiovascular death and heart failure (hf) hospitalization following a hospitalization for hf or need for outpatient iv diuretics, in adults with symptomatic chronic hf and eject...

Dosage: TABLET;ORAL

More Information on Dosage

VERQUVO family patents

Family Patents